Company intelligence / Profile preview

Exalenz Bioscience

Modi’in, Central, Israelmeridianbioscience.com ↗

Ownership: Private
Development stage: Commercial

Overview

Exalenz’s flagship product, the BreathID platform, is a non-invasive urea breath test system for rapid detection of H. pylori infection and other GI/liver conditions. The system is FDA-cleared and CE-marked; it delivers results in 10–15 minutes with high sensitivity and specificity. It has been adopted in over 400 U.S. medical centers and major labs[1][3][6].

Therapeutic areas: GastroenterologyOncologyInfectious Diseases
Modalities: Device
Industry: Metabolite Diagnostics

Partnerships

No major external pharma/biotech partnerships reported; now integrated into Meridian’s diagnostics business.

Beyond the preview

Go deeper on Exalenz Bioscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Exalenz Bioscience.

Explore the full profile